Evommune, Inc., a clinical-stage biotechnology company pioneering innovative treatments for inflammatory diseases, has closed a $50 million Series B financing round. Co-led by Arix Bioscience and current investors EQT Life Sciences and SymBiosis, the financing was supported by Amplitude Ventures and other new and existing investors, including Pivotal bioVenture Partners and Andera Partners. This marks a major milestone for Evommune, as the company continues to revolutionize treatments for inflammatory diseases.
We are thrilled to join forces with Evommune, a pioneering biotechnology company that utilizes a cutting-edge human tissue screening platform for its drug discovery and translational medicine decisions.
With Mark Chin, Managing Director at Arix Bioscience, at the helm, Evommune is primed to make strides in the medical field with its lead investigational medicine, EVO101, which targets interleukin 1 receptor-associated kinase 4 (IRAK4), as well as its other programs targeting MRGPRX2 and protein kinase C (PKC) theta (PKCθ). We have faith that the experienced leadership team will be able to realize the full potential of these groundbreaking therapies.
Evommune has recently raised capital to support its three priority pipeline programs, all of which are targeting highly prevalent inflammatory diseases. One of these programs, EVO101, is a novel small molecule inhibitor of the IRAK4 that is currently being evaluated in a Phase 2a proof-of-concept trial for atopic dermatitis.
Results from the trial are expected later this year. Additionally, Evommune is working on EVO756, a preclinical molecule designed to target mast cells, as well as a discovery program that focuses on autoimmune diseases via PKCθ modulation.
At Evommune, we are committed to advancing the immunology landscape and innovating the treatments of chronic inflammatory diseases. With the new funding, we are now equipped to undertake an ambitious pipeline of projects that will continue to 2025, with multiple milestones planned over the next two years.
We are grateful to our existing investors and welcome new ones who share our vision and enthusiasm. Together, we can strive to reduce the three out of five people worldwide who die from these diseases.
About Evommune, Inc.
Evommune, Inc. is revolutionizing the way we treat inflammatory diseases with their cutting-edge biotechnology. By employing a unique and dynamic human tissue-based approach, they are discovering, developing, and delivering therapies that can address symptoms and halt progressive diseases. Founded in 2020 by a team of veteran R&D experts and biotech builders, Evommune is on the forefront of immunology and is based in Palo Alto, California.